EU GMP Annex 1, Section 2 - Pharmaceutical Quality System

What it says

Sterile product manufacturers must apply Quality Risk Management principles throughout their Pharmaceutical Quality System, with a holistic Contamination Control Strategy that identifies and controls all critical points of contamination risk across facilities, equipment, personnel and processes.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• The Contamination Control Strategy introduced in this section is the organizing concept for the entire modern Annex 1, tying together facility design, personnel practices, monitoring and process controls into one documented, risk-based framework rather than a collection of separate requirements.
• Because the Contamination Control Strategy is expected to be a living document, it should be reviewed and updated as new risks are identified or as monitoring data reveals gaps, not written once and left static.
• Quality Risk Management applied under this section is meant to be genuinely risk-based and site-specific, not a generic template applied identically across different facilities and product types.

What inspectors look for

• Whether a genuine, site-specific Contamination Control Strategy exists, is current, and is actually used to drive decisions about facility design, monitoring and process control.
• Whether the Contamination Control Strategy is updated in response to new risks, monitoring trends or deviations, rather than remaining static after initial creation.
• Whether the risk management principles applied are traceable to actual site-specific data and conditions rather than copied from a generic industry template.

Related regulations